Edition:
India

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

5.49USD
20 Apr 2018
Change (% chg)

$-0.17 (-3.00%)
Prev Close
$5.66
Open
$5.62
Day's High
$5.67
Day's Low
$5.47
Volume
218,023
Avg. Vol
303,616
52-wk High
$5.85
52-wk Low
$1.93

Chart for

About

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $329.60
Shares Outstanding(Mil.): 109.14
Dividend: --
Yield (%): --

Financials

BRIEF-Cerus’ Redes Phase 3 Red Blood Cell Study Expands Into The Continental U.S.

* ’ REDES PHASE 3 RED BLOOD CELL STUDY EXPANDS INTO THE CONTINENTAL U.S.

02 Apr 2018

BRIEF-Cerus Announces The Fourth Biologics License Application Approval For A U.S. Blood Center Customer

* CERUS ANNOUNCES THE FOURTH BIOLOGICS LICENSE APPLICATION (BLA) APPROVAL FOR A U.S. BLOOD CENTER CUSTOMER

13 Mar 2018

BRIEF-Cerus Corp Reports Q4 Loss Per Share $0.10

* ORATION REPORTS RECORD FOURTH QUARTER AND YEAR END 2017 RESULTS

09 Mar 2018

BRIEF-Cerus Announces Pricing Of Public Offering Of Common Stock

* CERUS CORP - ‍PRICING OF PUBLIC OFFERING OF ITS COMMON STOCK FOR PROCEEDS OF $50.0 MILLION, BEFORE DEDUCTING ESTIMATED OFFERING EXPENSES PAYABLE BY CERUS​ Source text for Eikon: Further company coverage:

31 Jan 2018

BRIEF-Cerus Announces Public Offering Of Common Stock

* CERUS CORP - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

31 Jan 2018

BRIEF-Cerus - Chronic Anemia Phase 3 Study Met Primary Efficacy And Safety Endpoints

* CERUS REPORTS POSITIVE TOP-LINE RESULTS FROM CHRONIC ANEMIA PHASE 3 STUDY EVALUATING INTERCEPT RED BLOOD CELLS IN THALASSEMIA PATIENTS

24 Jan 2018

BRIEF-Cerus Corp Expects Full Year 2017 Product Revenue To Be $43.6 Million

* CERUS CORP - CERUS' UNAUDITED PRELIMINARY PRODUCT REVENUE FOR Q4 OF 2017 WAS $16.2 MILLION

08 Jan 2018

BRIEF-Cerus receives IDE approval to initiate phase iii recepi study

* Cerus Corporation receives IDE approval to initiate phase iii recepi study Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Cerus Corp reports Q3 loss per share $0.12

* Q3 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S

03 Nov 2017

BRIEF-Cerus and Kedrion Biopharma enter distribution agreement for full INTERCEPT blood system portfolio

* Cerus and Kedrion Biopharma enter distribution agreement for the full INTERCEPT blood system portfolio in Italy

31 Oct 2017

Competitors

  Price Chg
Terumo Corp (4543.T) ¥6,190 +100.00
Grifols SA (GRLS.MC) €23.41 +0.03
Grifols SA (GRLSbn.MC) €17.08 -0.04

Earnings vs. Estimates